 Intravesical bacillus Calmette-Guerin patients high-risk superficial bladder cancer Intravesical bacillus Calmette-Guerin BCG treatment patients aggressive superficial transitional cell carcinoma bladder cTa cTis patients previous history recurrent superficial disease treatment failures intravesical therapy Thirty-six patients treatment treatment failures Twenty-seven patients tumors patients cTis mean follow-up period months Disease progression patients muscle invasive disease Patients history previous events tumor recurrence positive urinary cytology multicentric disease patients characteristics BCG effective agent superficial transitional cell carcinoma bladder high-risk group patients previous intravesical therapy BCG group patients prior radical surgery